ReviewVeterinary research communications2026
Systemic use of terbinafine in veterinary medicine: A review of pharmacokinetic studies.
Review in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Terbinafine is an orally and topically active allylamine antifungal agent with fungistatic and fungicidal action. Its mechanism of action is the competitive inhibition of squalene epoxidase which leads to squalene accumulation and ergosterol depletion in the cell membrane. Clinically relevant pathogens can include but are not limited to: Aspergillus spp., Candida spp., Blastomyces dermatitidis, Histoplasma capsulatum, Emydomyces testavorans, Ophidiomyces ophiodiicola, and Batrachochytrium dendrobatidis. Terbinafine is an antifungal drug that has been used successfully in humans with few adverse effects. It is not licensed in the United States for systemic use in veterinary medicine but is routinely used in an extra label manner to treat fungal infections. Terbinafine has been well tolerated in domesticated and non-domesticated animals that have been studied. The studies that are available suggest that species differences exist in pharmacokinetics and further research is necessary to establish recommended doses in individual species. Due to the variation, terbinafine should be investigated on a species-by-species basis to determine its effective and safe use, thus ensuring the wellbeing of animals.
Indexed as
Identifiers
42053962What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.